株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

癌のコンパニオン診断検査の世界市場 - 産業分析・市場規模・市場シェア・成長率・各種動向・将来予測:技術 (タンパク質検出・DNA検出)・バイオマーカー・癌区分別

Companion Diagnostic Tests in Oncology Market (Detection Technique - Protein Detection, DNA Detection; Biomarker; Cancer Type; End User) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025

発行 Transparency Market Research 商品コード 279441
出版日 ページ情報 英文 232 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=112.34円で換算しております。
Back to Top
癌のコンパニオン診断検査の世界市場 - 産業分析・市場規模・市場シェア・成長率・各種動向・将来予測:技術 (タンパク質検出・DNA検出)・バイオマーカー・癌区分別 Companion Diagnostic Tests in Oncology Market (Detection Technique - Protein Detection, DNA Detection; Biomarker; Cancer Type; End User) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025
出版日: 2017年06月01日 ページ情報: 英文 232 Pages
概要

当レポートでは、癌のコンパニオン診断検査の市場を調査し、市場の定義と概要、市場成長への各種影響因子および市場機会の分析、検出技術・バイオマーカータイプ・癌のタイプ・エンドユーザー・地域/主要国別の動向と市場規模の推移と予測、競合環境、主要企業のプロファイルなどをまとめています。

第1章 序章

第2章 前提因子・調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

  • イントロダクション
  • 概要
  • 主要市場指標
  • 市場力学
    • 成長推進因子
    • 成長阻害因子
    • 市場機会
  • 市場分析・予測:収益
  • ポーターのファイブフォース分析
  • 市場の展望
  • 将来の動向:RGT (Response-guided Therapy)・テラノスティック (theranostic)
  • FDAのBreakthrough Therapy指定:コンパニオン診断検査
  • 概要:FDA承認済みin-vitroコンパニオン診断検査
  • コンパニオン診断と法規制上の要件:地域別
  • コンパニオン診断検査:主要企業
  • パイプラインの概要:主要企業

第5章 市場分析・予測:検出技術別

  • イントロダクション・定義
  • 主要調査結果・発展動向
  • 主要動向
  • 市場予測
    • タンパク質検出
      • 免疫組織化学
    • DNA検出
      • ポリメラーゼ連鎖反応 (PCR)
      • 次世代シーケンシング
      • In-Situハイブリダイゼーション
    • その他
  • 市場の魅力の分析

第6章 市場分析・予測:バイオマーカー別

  • イントロダクション・定義
  • 主要調査結果・発展動向
  • 主要動向
  • 市場予測
    • EGFR
    • KRAS
    • BRAF V600E
    • HER2
    • その他
  • 市場の魅力の分析

第7章 市場分析・予測:癌タイプ別

  • イントロダクション・定義
  • 主要調査結果・発展動向
  • 主要動向
  • 市場予測
    • 乳癌
    • 肝臓癌
    • 肺癌
    • 大腸癌
    • 黒色腫
    • その他
  • 市場の魅力の分析

第8章 市場分析・予測:エンドユーザー別

  • イントロダクション・定義
  • 主要調査結果・発展動向
  • 主要動向
  • 市場予測
    • 病院
    • 専門クリニック
    • 診断ラボ
    • その他
  • 市場の魅力の分析

第9章 市場分析・予測:地域別

  • 主要調査結果
  • 政策・法規制
  • 市場規模の予測
  • 市場の魅力の分析

第10章 北米市場の分析・予測

  • イントロダクション
    • 主要調査結果
    • 政策・法規制
    • 主要動向
  • 市場予測:検出技術別
  • 市場予測:バイオマーカー別
  • 市場予測:癌タイプ別
  • 市場予測:エンドユーザー別
  • 市場予測:国別
    • 米国
    • カナダ
  • 市場の魅力の分析

第11章 欧州市場の分析・予測

  • イントロダクション
    • 主要調査結果
    • 政策・法規制
    • 主要動向
  • 市場予測:検出技術別
  • 市場予測:バイオマーカー別
  • 市場予測:癌タイプ別
  • 市場予測:エンドユーザー別
  • 市場予測:国別
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スぺイン
    • ロシア
    • その他
  • 市場の魅力の分析

第12章 アジア太平洋市場の分析・予測

  • イントロダクション
    • 主要調査結果
    • 政策・法規制
    • 主要動向
  • 市場予測:検出技術別
  • 市場予測:バイオマーカー別
  • 市場予測:癌タイプ別
  • 市場予測:エンドユーザー別
  • 市場予測:国別
    • インド
    • 中国
    • 日本
    • オーストラリア&ニュージーランド
    • その他
  • 市場の魅力の分析

第13章 ラテンアメリカ市場の分析・予測

  • イントロダクション
    • 主要調査結果
    • 政策・法規制
    • 主要動向
  • 市場予測:検出技術別
  • 市場予測:バイオマーカー別
  • 市場予測:癌タイプ別
  • 市場予測:エンドユーザー別
  • 市場予測:国別
    • ブラジル
    • メキシコ
    • その他
  • 市場の魅力の分析

第14章 中東・アフリカ市場の分析・予測

  • イントロダクション
    • 主要調査結果
    • 政策・法規制
    • 主要動向
  • 市場予測:検出技術別
  • 市場予測:バイオマーカー別
  • 市場予測:癌タイプ別
  • 市場予測:エンドユーザー別
  • 市場予測:国別
    • 南アフリカ
    • GCC諸国
    • その他
  • 市場の魅力の分析

第15章 競合環境

  • 参入企業:競合マトリックス
  • 企業シェア実績
  • 企業プロファイル
    • Abbott
    • F. Hoffman LA Roche Ltd.
    • Genomic Health, Inc.
    • QIAGEN
    • Agilent Technologies, Inc.
    • AGENDIA NV
    • bioMerieux SA
    • Illumina, Inc.
    • Siemens Healthcare GmBH
    • Thermo Fisher Scientific, Inc.
    • BioGenex

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Title:
Companion Diagnostic Tests in Oncology Market
(Detection Technique - Protein Detection, DNA Detection (Polymerase Chain Reaction, Next Generation Sequencing, and In Situ Hybridization (Fluorescence In Situ Hybridization, and Chromogenic In Situ Hybridization)); Biomarker - EGFR, BRAF V600E, KRAS, and HER2; Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, and Melanoma; End User - Pharmaceutical and Biotechnology Companies, Medical Device Companies, and Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025.

Global Companion Diagnostic Tests in Oncology Market: Overview

Companion diagnostics (CDx) are the tests or assays intended to assist physicians in making effective treatment decisions based on the patient response to the ongoing treatment with a targeted therapeutic area. These tests are an indicative measure of the patient sub-population that will be benefitted from the suggested drug / therapy, and differentiates the non-responder patients from the one's who will respond to the treatment option. Hence, these diagnostic tests ensure the commercialization of safer and efficient targeted therapeutics with minimal or no side effects, while ensuring economic benefits to pharmaceutical companies, and the patients as well. Of late, many leading pharmaceutical companies are focusing on regulating the costs incurred in the drug discovery, development and commercialization process. This effort involves the development of companion diagnostic along with a targeted therapeutic area, and this has led to increasing collaborations between pharmaceutical and medical device companies, to co-develop a drug with companion diagnostic test. The tremendous research in the field of oncology, has led to the discovery of numerous biomarkers facilitating disease diagnosis and treatment, and these are some major factors contributing to the increasing demand for personalized medicine, and companion diagnostics tests in oncology.

The market overview section of the report comprises qualitative analysis of the overall companion diagnostic tests in oncology market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter's five force analysis and market attractiveness analysis. In addition, market opportunity analysis for detection techniques, biomarker, and type of cancer, and key industry developments has also been provided. Key industry developments include the major events occurred in past decade and are expected to occur during the forecast period which are likely to affect the market dynamics.

Global Companion Diagnostic Tests in Oncology Market: Segmentation

The global companion diagnostic tests in oncology market has been segmented on the basis of detection technique, biomarker, cancer type, and end-user. On the basis of detection technique, the global companion diagnostic tests in oncology market is segmented into protein detection technique, DNA detection technique, and other detection techniques. The DNA detection techniques are further segmented into polymerase chain reaction, next generation sequencing, and in situ hybridization detection techniques. The biomarker segment of the global companion diagnostic tests in oncology market is segmented into EGFR, HER2, KRAS, BRAF V600E, and other biomarkers. The cancer type segment of the global companion diagnostic tests in oncology market is further segmented into breast cancer, lung cancer, liver cancer, melanoma, colorectal cancer, and other cancers. The end-user segment includes pharmaceutical & biotechnology companies, medical device companies, research institutes, and other end-users. The market for these detection techniques, biomarker, cancer types and end users has been extensively analyzed on the basis of factors such as incidence, prevalence of diseases, usage pattern of detection techniques, sales revenue of the tests, geographic presence of the market players and technological developments. The market size and forecast in terms of revenue (US$ Mn) for each of these segments have been provided for the period 2015 to 2025, considering 2016 as the base year. The report also provides the compounded annual growth rate (CAGR) for each segment for the forecast period 2017 to 2025.

Global Companion Diagnostic Tests in Oncology Market: Regional Outlook

Geographically, the companion diagnostic tests in oncology market has been segmented into five regions namely; North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The market size and forecast for each region has been provided for the period 2015 to 2025, in terms of detection techniques, biomarker, cancer type, and end-user along with the CAGR (%) for the forecast period 2017-2025.

Global Companion Diagnostic Tests in Oncology Market: Competitive Landscape

The report also provides a section on the competitive landscape, wherein the market share analysis of leading players in the global companion diagnostic tests in oncology market, in terms of percentage share in 2016 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market share. The report concludes with the profiles of major players in the global Companion Diagnostic Tests in Oncology market such as F. Hoffman LA Roche Ltd., QIAGEN, Illumina, Inc., Abbott, Agilent Technologies, Inc., Genomic Health, Inc., bioMerieux SA, BioGenex, AGENDIA NV, Siemens Healthcare GmBH, and Thermo Fisher Scientific, Inc., among others. The major market players are evaluated on various parameters such as company overview, financial overview, product portfolio, business strategies and recent developments.

The global companion diagnostic tests in oncology market is segmented as follows:

Global Companion Diagnostic Tests in Oncology Market, By Detection Technique

  • Protein Detection
  • DNA Detection
  • Polymerase Chain Reaction (PCR)
  • Next Gen Sequencing (NGS)
  • In Situ Hybridization
  • Fluorescence In Situ Hybridization (FISH)
  • Chromogenic In Situ Hybridization (CISH)
  • Others

Global Companion Diagnostic Tests in Oncology Market, by Biomarker

  • EGFR
  • KRAS
  • HER2
  • BRAF V600E
  • Others

Global Companion Diagnostic Tests in Oncology Market, by Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Liver Cancer
  • Melanoma
  • Others

Global Companion Diagnostic Tests in Oncology Market, by End Users

  • Pharmaceutical & Biotechnology Companies
  • Medical Device Companies
  • Research Institutes
  • Others

Global Companion Diagnostic Tests in Oncology Market, by Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Digital Companion Diagnostics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Detection Technique Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Key Market Indicators
  • 4.4. Market Dynamics
    • 4.4.1. Drivers
    • 4.4.2. Restraints
    • 4.4.3. Opportunity
  • 4.5. Global Digital Companion Diagnostics Market Analysis and Forecasts, 2015-2025
    • 4.5.1. Market Revenue Projections (US$ Mn)
  • 4.6. Porter's Five Force Analysis
  • 4.7. Market Outlook
  • 4.8. Future Trends: response-guided therapy, theranostic
  • 4.9. FDA breakthrough therapies: For Companion Diagnostic Tests
  • 4.10. Overview FDA approved in-vitro Companion Diagnostic Tests
  • 4.11. Companion Diagnostics and regulatory requirements : region wise
  • 4.12. Companion Diagnostic Tests - Intended Diagnostics Type - Market Players
  • 4.13. Pipeline Overview: Major market players

5. Global Digital Companion Diagnostics Market Analysis and Forecasts, By Detection Technique

  • 5.1. Introduction & Definition
  • 5.2. Key Findings / Developments
  • 5.3. Key Trends
  • 5.4. Market Value Forecast By Detection Technique , 2015-2025
    • 5.4.1. Protein Detection
      • 5.4.1.1. Immunohistochemistry
    • 5.4.2. DNA Detection
      • 5.4.2.1. Polymerase Chain Reaction
      • 5.4.2.2. Next Gen Sequencing
      • 5.4.2.3. In-Situ Hybridization
    • 5.4.3. Others
  • 5.5. Market Attractiveness By Detection Technique

6. Global Digital Companion Diagnostics Market Analysis and Forecasts, By Bio-markers

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Key Trends
  • 6.4. Market Value Forecast By Bio-markers, 2015-2025
    • 6.4.1. EGFR
    • 6.4.2. KRAS
    • 6.4.3. BRAF V600E
    • 6.4.4. HER2
    • 6.4.5. Others
  • 6.5. Market Attractiveness By Bio-markers

7. Global Digital Companion Diagnostics Market Analysis and Forecasts, By Cancer Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Key Trends
  • 7.4. Market Value Forecast By Cancer Type , 2015-2025
    • 7.4.1. Breast Cancer
    • 7.4.2. Liver Cancer
    • 7.4.3. Lung Cancer
    • 7.4.4. Colorectal Cancer
    • 7.4.5. Melanoma
    • 7.4.6. Others
  • 7.5. Market Attractiveness By Cancer Type

8. Global Digital Companion Diagnostics Market Analysis and Forecasts, By End User

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Key Trends
  • 8.4. Market Value Forecast By End User , 2015-2025
    • 8.4.1. Hospitals
    • 8.4.2. Specialty Clinics
    • 8.4.3. Diagnostic Labs
    • 8.4.4. Others
  • 8.5. Market Attractiveness By End User

9. Global Digital Companion Diagnostics Market Analysis and Forecasts, By Region

  • 9.1. Key Findings
  • 9.2. Policies and Regulations
  • 9.3. Market Value Forecast By Region
    • 9.3.1. North America
    • 9.3.2. Europe
    • 9.3.3. Asia Pacific
    • 9.3.4. Latin America
    • 9.3.5. Middle East and Africa
  • 9.4. Market Attractiveness By Country/Region

10. North America Digital Companion Diagnostics Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
    • 10.1.2. Policies and Regulations
    • 10.1.3. Key Trends
  • 10.2. Market Value Forecast By Detection Technique, 2015-2025
    • 10.2.1. Protein Detection
      • 10.2.1.1. Immunohistochemistry
    • 10.2.2. DNA Detection
      • 10.2.2.1. Polymerase Chain Reaction
      • 10.2.2.2. Next Gen Sequencing
      • 10.2.2.3. In-Situ Hybridization
    • 10.2.3. Others
  • 10.3. Market Value Forecast By Bio-markers, 2015-2025
    • 10.3.1. EGFR
    • 10.3.2. KRAS
    • 10.3.3. BRAF V600E
    • 10.3.4. HER2
    • 10.3.5. Others
  • 10.4. Market Value Forecast By Cancer Type , 2015-2025
    • 10.4.1. Breast Cancer
    • 10.4.2. Liver Cancer
    • 10.4.3. Lung Cancer
    • 10.4.4. Colorectal Cancer
    • 10.4.5. Melanoma
    • 10.4.6. Others
  • 10.5. Market Value Forecast By End User , 2015-2025
    • 10.5.1. Hospitals
    • 10.5.2. Specialty Clinics
    • 10.5.3. Diagnostic Labs
    • 10.5.4. Others
  • 10.6. Market Value Forecast By Country , 2015-2025
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Detection Technique
    • 10.6.2. By Bio-markers
    • 10.6.3. By Cancer Type
    • 10.6.4. By End User
    • 10.6.5. By Country

11. Europe Digital Companion Diagnostics Market Analysis and Forecast

    11.1. Introduction
    • 11.1.1. Key Findings
    • 11.1.2. Policies and Regulations
    • 11.1.3. Key Trends
  • 11.2. Market Value Forecast By Detection Technique , 2015-2025
    • 11.2.1. Protein Detection
      • 11.2.1.1. Immunohistochemistry
    • 11.2.2. DNA Detection
      • 11.2.2.1. Polymerase Chain Reaction
      • 11.2.2.2. Next Gen Sequencing
      • 11.2.2.3. In-Situ Hybridization
    • 11.2.3. Others
  • 11.3. Market Value Forecast By Bio-markers , 2015-2025
    • 11.3.1. EGFR
    • 11.3.2. KRAS
    • 11.3.3. BRAF V600E
    • 11.3.4. HER2
    • 11.3.5. Others
  • 11.4. Market Value Forecast By Cancer Type , 2015-2025
    • 11.4.1. Breast Cancer
    • 11.4.2. Liver Cancer
    • 11.4.3. Lung Cancer
    • 11.4.4. Colorectal Cancer
    • 11.4.5. Melanoma
    • 11.4.6. Others
  • 11.5. Market Value Forecast By End User , 2015-2025
    • 11.5.1. Hospitals
    • 11.5.2. Specialty Clinics
    • 11.5.3. Diagnostic Labs
    • 11.5.4. Others
  • 11.6. Market Value Forecast By Country , 2015-2025
    • 11.6.1. U.K.
    • 11.6.2. Germany
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Russia
    • 11.6.7. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Detection Technique
    • 11.7.2. By Bio-markers
    • 11.7.3. By Cancer Type
    • 11.7.4. By End User
    • 11.7.5. By Country

12. Asia Pacific Digital Companion Diagnostics Market Analysis and Forecast 12.1. Introduction

    • 12.1.1. Key Findings
    • 12.1.2. Policies and Regulations
    • 12.1.3. Key Trends
  • 12.2. Market Value Forecast By Detection Technique , 2015-2025
    • 12.2.1. Protein Detection
      • 12.2.1.1. Immunohistochemistry
    • 12.2.2. DNA Detection
      • 12.2.2.1. Polymerase Chain Reaction
      • 12.2.2.2. Next Gen Sequencing
      • 12.2.2.3. In-Situ Hybridization
    • 12.2.3. Others
  • 12.3. Market Value Forecast By Bio-markers , 2015-2025
    • 12.3.1. EGFR
    • 12.3.2. KRAS
    • 12.3.3. BRAF V600E
    • 12.3.4. HER2
    • 12.3.5. Others
  • 12.4. Market Value Forecast By Cancer Type , 2015-2025
    • 12.4.1. Breast Cancer
    • 12.4.2. Liver Cancer
    • 12.4.3. Lung Cancer
    • 12.4.4. Colorectal Cancer
    • 12.4.5. Melanoma
    • 12.4.6. Others
  • 12.5. Market Value Forecast By End User , 2015-2025
    • 12.5.1. Hospitals
    • 12.5.2. Specialty Clinics
    • 12.5.3. Diagnostic Labs
    • 12.5.4. Others
  • 12.6. Market Value Forecast By Country , 2015-2025
    • 12.6.1. India
    • 12.6.2. China
    • 12.6.3. Japan
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Detection Technique
    • 12.7.2. By Bio-markers
    • 12.7.3. By Cancer Type
    • 12.7.4. By End User
    • 12.7.5. By Country

13. Latin America Digital Companion Diagnostics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
    • 13.1.2. Policies and Regulations
    • 13.1.4. Key Trends
  • 13.2. Market Value Forecast By Detection Technique , 2015-2025
    • 13.2.1. Protein Detection
      • 13.2.1.1. Immunohistochemistry
    • 13.2.2. DNA Detection
      • 13.2.2.1. Polymerase Chain Reaction
      • 13.2.2.2. Next Gen Sequencing
      • 13.2.2.3. In-Situ Hybridization
    • 13.2.3. Others
  • 13.3. Market Value Forecast By Bio-markers , 2015-2025
    • 13.3.1. EGFR
    • 13.3.2. KRAS
    • 13.3.3. BRAF V600E
    • 13.3.4. HER2
    • 13.3.5. Others
  • 13.4. Market Value Forecast By Cancer Type , 2015-2025
    • 13.4.1. Breast Cancer
    • 13.4.2. Liver Cancer
    • 13.4.3. Lung Cancer
    • 13.4.4. Colorectal Cancer
    • 13.4.5. Melanoma
    • 13.4.6. Others
  • 13.5. Market Value Forecast By End User , 2015-2025
    • 13.5.1. Hospitals
    • 13.5.2. Specialty Clinics
    • 13.5.3. Diagnostic Labs
    • 13.5.4. Others
  • 13.6. Market Value Forecast By Country , 2015-2025
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Detection Technique
    • 13.7.2. By Bio-markers
    • 13.7.3. By Cancer Type
    • 13.7.4. By End User
    • 13.7.5. By Country

14. Middle East and Africa Digital Companion Diagnostics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
    • 14.1.2. Policies and Regulations
    • 14.1.4. Key Trends
  • 14.2. Market Value Forecast By Detection Technique , 2015-2025
    • 14.2.1. Protein Detection
      • 14.2.1.1. Immunohistochemistry
    • 14.2.2. DNA Detection
      • 14.2.2.1. Polymerase Chain Reaction
      • 14.2.2.2. Next Gen Sequencing
      • 14.2.2.3. In-Situ Hybridization
    • 14.2.3. Others
  • 14.3. Market Value Forecast By Bio-markers , 2015-2025
    • 14.3.1. EGFR
    • 14.3.2. KRAS
    • 14.3.3. BRAF V600E
    • 14.3.4. HER2
    • 14.3.5. Others
  • 14.4. Market Value Forecast By Cancer Type , 2015-2025
    • 14.4.1. Breast Cancer
    • 14.4.2. Liver Cancer
    • 14.4.3. Lung Cancer
    • 14.4.4. Colorectal Cancer
    • 14.4.5. Melanoma
    • 14.4.6. Others
  • 14.5. Market Value Forecast By End User , 2015-2025
    • 14.5.1. Hospitals
    • 14.5.2. Specialty Clinics
    • 14.5.3. Diagnostic Labs
    • 14.5.4. Others
  • 14.6. Market Value Forecast By Country , 2015-2025
    • 14.6.1. South Africa
    • 14.6.2. GCC Countries
    • 14.6.3. Rest of Middle East and Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Detection Technique
    • 14.7.2. By Bio-markers
    • 14.7.4. By Cancer Type
    • 14.7.5. By End User
    • 14.7.6. By Country

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 15.2. Market Share Analysis By Company (2015)
  • 15.3. Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
    • 15.3.1. Abbott
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strengths)
      • 15.3.1.2. Financial Overview
      • 15.3.1.3. Product Portfolio
      • 15.3.1.4. SWOT Analysis
      • 15.3.1.5. Strategic Overview
    • 15.3.2. F. Hoffman LA Roche Ltd.
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strengths)
      • 15.3.2.2. Financial Overview
      • 15.3.2.3. Product Portfolio
      • 15.3.2.4. SWOT Analysis
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Genomic Health, Inc.
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strengths)
      • 15.3.3.2. Financial Overview
      • 15.3.3.3. Product Portfolio
      • 15.3.3.4. SWOT Analysis
      • 15.3.3.5. Strategic Overview
    • 15.3.4. QIAGEN
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strengths)
      • 15.3.4.2. Financial Overview
      • 15.3.4.3. Product Portfolio
      • 15.3.4.4. SWOT Analysis
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Agilent Technologies, Inc.
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strengths)
      • 15.3.5.2. Financial Overview
      • 15.3.5.3. Product Portfolio
      • 15.3.5.4. SWOT Analysis
      • 15.3.5.5. Strategic Overview
    • 15.3.6. AGENDIA NV
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strengths)
      • 15.3.6.2. Financial Overview
      • 15.3.6.3. Product Portfolio
      • 15.3.6.4. SWOT Analysis
      • 15.3.6.5. Strategic Overview
    • 15.3.7. bioMerieux SA
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strengths)
      • 15.3.7.2. Financial Overview
      • 15.3.7.3. Product Portfolio
      • 15.3.7.4. SWOT Analysis
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Illumina, Inc.
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strengths)
      • 15.3.8.2. Financial Overview
      • 15.3.8.3. Product Portfolio
      • 15.3.8.4. SWOT Analysis
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Siemens Healthcare GmBH
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strengths)
      • 15.3.9.2. Financial Overview
      • 15.3.9.3. Product Portfolio
      • 15.3.9.4. SWOT Analysis
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Thermo Fisher Scientific, Inc.
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strengths)
      • 15.3.10.2. Financial Overview
      • 15.3.10.3. Product Portfolio
      • 15.3.10.4. SWOT Analysis
      • 15.3.10.5. Strategic Overview
    • 15.3.11. BioGenex
      • 15.3.11.1. Company Overview (HQ, Business Segments, Employee Strengths)
      • 15.3.11.2. Financial Overview
      • 15.3.11.3. Product Portfolio
      • 15.3.11.4. SWOT Analysis
      • 15.3.11.5. Strategic Overview

List of Tables

  • Table 01: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique, 2015-2025
  • Table 02: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015-2025
  • Table 03: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015-2025
  • Table 04: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015-2025
  • Table 05: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015-2025
  • Table 06: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015-2025
  • Table 07: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Region, 2015-2025
  • Table 08: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Country, 2015-2025
  • Table 09: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique, 2015-2025
  • Table 10: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015-2025
  • Table 11: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015-2025
  • Table 12: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015-2025
  • Table 13: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015-2025
  • Table 14: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015-2025
  • Table 15: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Country, 2015-2025
  • Table 16: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique, 2015-2025
  • Table 17: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015-2025
  • Table 18: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015-2025
  • Table 19: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015-2025
  • Table 20: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015-2025
  • Table 21: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015-2025
  • Table 22: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Country, 2015-2025
  • Table 23: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique,
  • Table 24: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015-2025
  • Table 25: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015-2025
  • Table 26: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015-2025
  • Table 27: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015-2025
  • Table 28: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015-2025
  • Table 29: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Country, 2015-2025
  • Table 30: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique, 2015-2025
  • Table 31: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015-2025
  • Table 32: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015-2025
  • Table 33: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015-2025
  • Table 34: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015-2025
  • Table 35: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015-2025
  • Table 36: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Country, 2015-2025
  • Table 37: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique, 2015-2025
  • Table 38: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015-2025
  • Table 39: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015-2025
  • Table 40: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015-2025
  • Table 41: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015-2025
  • Table 42: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015-2025

List of Figures

  • Figure 01: Global Companion Diagnostic Tests in Oncology, Market Size (US$ Mn) Forecast, 2015-2025
  • Figure 02: Global Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type (2016)
  • Figure 03: Global Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker (2016)
  • Figure 04: Global Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique (2016)
  • Figure 05: Global Companion Diagnostic Tests in Oncology Market Value Share, by Region (2016)
  • Figure 06: Global Companion Diagnostic Tests in Oncology Market Value Share, by End-user (2016)
  • Figure 07: Global Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2017 and 2025
  • Figure 08: Global Companion Diagnostic Tests in Oncology Market Attractiveness, by Detection Technique, 2017-2025
  • Figure 09: Global Protein Detection Technique in Companion Diagnostic Tests, Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2025
  • Figure 10: Global DNA Detection Technique in Companion Diagnostic Tests, Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2025
  • Figure 11: Global Other Detection Techniques in Companion Diagnostic Tests, Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2025
  • Figure 12: Global Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
  • Figure 13: Global Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017-2025
  • Figure 14: Global Companion Diagnostic Tests in Oncology Market, by EGFR Biomarker, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015-2025
  • Figure 15: Global Companion Diagnostic Tests in Oncology Market, by KRAS Biomarker, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015-2025
  • Figure 16: Global Companion Diagnostic Tests in Oncology Market, by BRAF V600E Biomarker, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015-2025
  • Figure 17: Global Companion Diagnostic Tests in Oncology Market, by HER2 Biomarker, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015-2025
  • Figure 18: Global Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2017 and 2025
  • Figure 19: Global Companion Diagnostic Tests in Oncology Market Attractiveness, by Cancer Type, 2017-2025
  • Figure 20: Global Companion Diagnostic Tests in Oncology Market, by Breast Cancer, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015-2025
  • Figure 21: Global Companion Diagnostic Tests in Oncology Market, by Lung Cancer, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015-2025
  • Figure 22: Global Companion Diagnostic Tests in Oncology Market, by Liver Cancer, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015-2025
  • Figure 23: Global Companion Diagnostic Tests in Oncology Market, by Colorectal Cancer, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015-2025
  • Figure 24: Global Companion Diagnostic Tests in Oncology Market, by Melanoma Cancer, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015-2025
  • Figure 25: Global Companion Diagnostic Tests in Oncology Market, by Other Cancers, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015-2025
  • Figure 26: Global Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2017 and 2025
  • Figure 27: Global Companion Diagnostic Tests in Oncology Market Attractiveness, by End-user, 2017-2025
  • Figure 28: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Pharmaceutical & Biotechnology Companies, 2015-2025
  • Figure 29: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Medical Device Companies, 2015-2025
  • Figure 30: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Research Laboratories, 2015-2025
  • Figure 31: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Others, 2015-2025
  • Figure 32: Global Companion Diagnostic Tests in Oncology Market Value Share, by Region, 2017 and 2025
  • Figure 33: Global Companion Diagnostic Tests in Oncology Market Attractiveness, by Region, 2017-2025
  • Figure 34: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015-2025
  • Figure 35: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country, 2017 and 2025
  • Figure 36: North America Companion Diagnostic Tests in Oncology Market Attractiveness, by Country, 2017-2025
  • Figure 37: North America Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2017 and 2025
  • Figure 38: North America Companion Diagnostic Tests in Oncology Market Attractiveness, by Detection Technique, 2017-2025
  • Figure 39: North America Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
  • Figure 40: North America Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017-2025
  • Figure 41: North America Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2017 and 2025
  • Figure 42: North America Companion Diagnostic Tests in Oncology Market Attractiveness, by Cancer Type, 2017-2025
  • Figure 43: North America Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2017 and 2025
  • Figure 44: North America Companion Diagnostic Tests in Oncology Market Attractiveness, by End-user, 2017-2025
  • Figure 45: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015-2025
  • Figure 46: Europe Companion Diagnostic Tests in Oncology Market Value Share, by Country, 2017 and 2025
  • Figure 47: Europe Companion Diagnostic Tests in Oncology Market Attractiveness, by Country, 2017-2025
  • Figure 48: Europe Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2017 and 2025
  • Figure 49: Europe Companion Diagnostic Tests in Oncology Market Attractiveness, by Detection Technique, 2017-2025
  • Figure 50: Europe Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
  • Figure 51: Europe Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017-2025
  • Figure 52: Europe Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2017 and 2025
  • Figure 53: Europe Companion Diagnostic Tests in Oncology Market Attractiveness, by Cancer Type, 2017-2025
  • Figure 54: Europe Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2017 and 2025
  • Figure 55: Europe Companion Diagnostic Tests in Oncology Market Attractiveness, by End-user, 2017-2025
  • Figure 56: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015-2025
  • Figure 57: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share, by Country, 2017 and 2025
  • Figure 58: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness, by Country, 2017-2025
  • Figure 59: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2017 and 2025
  • Figure 60: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness, by Detection Technique, 2017-2025
  • Figure 61: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
  • Figure 62: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017-2025
  • Figure 63: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2017 and 2025
  • Figure 64: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness, by Cancer Type, 2017-2025
  • Figure 65: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2017 and 2025
  • Figure 66: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness, by End-user, 2017-2025
  • Figure 67: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015-2025
  • Figure 68: Latin America Companion Diagnostic Tests in Oncology Market Value Share, by Country, 2017 and 2025
  • Figure 69: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness, by Country, 2017-2025
  • Figure 70: Latin America Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2017 and 2025
  • Figure 71: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness, by Detection Technique, 2017-2025
  • Figure 72: Latin America Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
  • Figure 73: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017-2025
  • Figure 74: Latin America Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2017 and 2025
  • Figure 75: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness, by Cancer Type, 2017-2025
  • Figure 76: Latin America Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2017 and 2025
  • Figure 77: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness, by End-user, 2017-2025
  • Figure 78: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015-2025
  • Figure 79: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country, 2017 and 2025
  • Figure 80: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country, 2017-2025
  • Figure 81: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2017 and 2025
  • Figure 82: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2017-2025
  • Figure 83: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
  • Figure 84: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017-2025
  • Figure 85: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2017 and 2025
  • Figure 86: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2017-2025
  • Figure 87: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2017 and 2025
  • Figure 88: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2017-2025
  • Figure 89: Global Companion Diagnostic Tests in Oncology Market Share, by Company, 2016
Back to Top